MX390793B - Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio. - Google Patents
Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio.Info
- Publication number
- MX390793B MX390793B MX2019013574A MX2019013574A MX390793B MX 390793 B MX390793 B MX 390793B MX 2019013574 A MX2019013574 A MX 2019013574A MX 2019013574 A MX2019013574 A MX 2019013574A MX 390793 B MX390793 B MX 390793B
- Authority
- MX
- Mexico
- Prior art keywords
- deuterated
- prodrugs
- sodium channel
- channel modulators
- sub
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- -1 DEUTERATED PYRIDONE AMIDES Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507172P | 2017-05-16 | 2017-05-16 | |
| US201762547718P | 2017-08-18 | 2017-08-18 | |
| PCT/US2018/032939 WO2018213426A1 (en) | 2017-05-16 | 2018-05-16 | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019013574A MX2019013574A (es) | 2019-12-18 |
| MX390793B true MX390793B (es) | 2025-03-21 |
Family
ID=62567801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013574A MX390793B (es) | 2017-05-16 | 2018-05-16 | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11358977B2 (enExample) |
| EP (1) | EP3625214B1 (enExample) |
| JP (1) | JP7104070B2 (enExample) |
| KR (1) | KR102714561B1 (enExample) |
| CN (1) | CN110740993B (enExample) |
| AU (1) | AU2018271110A1 (enExample) |
| BR (1) | BR112019024016A2 (enExample) |
| CA (1) | CA3063901A1 (enExample) |
| CL (1) | CL2019003239A1 (enExample) |
| CO (1) | CO2019013021A2 (enExample) |
| ES (1) | ES2927712T3 (enExample) |
| IL (1) | IL270680B (enExample) |
| MA (1) | MA49137A (enExample) |
| MX (1) | MX390793B (enExample) |
| UA (1) | UA124857C2 (enExample) |
| WO (1) | WO2018213426A1 (enExample) |
| ZA (1) | ZA201907619B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190343817A1 (en) * | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| GEAP202315648A (en) | 2018-11-02 | 2023-07-25 | Merck Sharp & Dohme Llc | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020140959A1 (zh) * | 2019-01-04 | 2020-07-09 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用 |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020151728A1 (zh) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| WO2020206119A1 (en) * | 2019-04-02 | 2020-10-08 | Vertex Pharmaceuticals Incorporated | Process for making pyridone amides and prodrugs thereof useful as modulators of sodium channels |
| WO2020219867A1 (en) * | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| US12528782B2 (en) | 2019-07-16 | 2026-01-20 | Bristol-Myers Squibb Company | Prodrugs in the modulation of interleukin |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| TW202115038A (zh) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| KR20230026404A (ko) | 2020-06-17 | 2023-02-24 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드 |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| TW202220962A (zh) * | 2020-08-19 | 2022-06-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 選擇性NaV抑制劑的結晶形式及其製備方法 |
| TW202214259A (zh) * | 2020-08-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種選擇性ＮａＶ抑制劑的前藥及其晶型 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| MX2023007244A (es) * | 2020-12-18 | 2023-06-29 | Glaxosmithkline Ip Dev Ltd | Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8. |
| EP4263540A1 (en) * | 2020-12-18 | 2023-10-25 | GlaxoSmithKline Intellectual Property Development Limited | Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors |
| CN116964065A (zh) * | 2021-02-26 | 2023-10-27 | 江苏恒瑞医药股份有限公司 | 一种选择性NaV抑制剂的可药用盐、结晶形式及其制备方法 |
| EP4334293A1 (en) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202600064T1 (it) | 2021-06-04 | 2026-03-09 | Vertex Pharma | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| US20250222012A1 (en) * | 2021-11-02 | 2025-07-10 | Schedule 1 Therapeutics, Inc. | Use of cannabinoid compositions for treating pain associated with small fiber neuropathy |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| CA3256486A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| PY2404093A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits |
| WO2024159285A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| PY2404641A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS |
| WO2024159287A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| AU2025211735A1 (en) | 2024-01-24 | 2026-07-16 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
| WO2026102309A1 (en) | 2024-11-07 | 2026-05-15 | Lutroo Imaging, Llc | Selective radiotracers and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| ATE480771T1 (de) | 2000-07-10 | 2010-09-15 | Vertex Pharma San Diego Llc | Ionenkanal-assayverfahren |
| JP2003034671A (ja) | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| WO2006011050A2 (en) | 2004-07-23 | 2006-02-02 | Pfizer Limited | Pyridine derivatives |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| CA2701946A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| MX2010003864A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| EP2212290B1 (en) | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| CA2741153A1 (en) | 2008-10-29 | 2010-05-06 | F. Hoffmann-La Roche Ag | Novel phenyl amide or pyridyl amide derivatives and their use as gpbar1 agonists |
| JP5405592B2 (ja) | 2008-12-23 | 2014-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ７モジュレーターとしてのジヒドロピリドンアミド |
| MX2011006904A (es) | 2008-12-26 | 2011-07-20 | Dainippon Sumitomo Pharma Co | Compuesto heterociclico biciclico novedoso. |
| KR101605061B1 (ko) | 2009-05-29 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체 |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| CA2771472A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US9656959B2 (en) | 2010-12-22 | 2017-05-23 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| KR101923367B1 (ko) | 2011-02-02 | 2018-12-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드 |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| MX2013010067A (es) | 2011-03-03 | 2014-01-31 | Concert Pharmaceuticals Inc | Derivados de compuestos de amino-heteroarilo sustituidos con pirazol. |
| CA2828456C (en) | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| US9163008B2 (en) | 2011-09-02 | 2015-10-20 | Purdue Pharma, L.P. | Pyrimidines as sodium channel blockers |
| BR112014009102A2 (pt) | 2011-10-26 | 2017-04-18 | Pfizer Ltd | compostos químicos |
| WO2013109521A1 (en) | 2012-01-16 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| CA2863892C (en) | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| BR112015018284B1 (pt) | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| CN105026373B (zh) * | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
-
2018
- 2018-05-16 KR KR1020197037074A patent/KR102714561B1/ko active Active
- 2018-05-16 AU AU2018271110A patent/AU2018271110A1/en not_active Abandoned
- 2018-05-16 JP JP2019563132A patent/JP7104070B2/ja not_active Expired - Fee Related
- 2018-05-16 MX MX2019013574A patent/MX390793B/es unknown
- 2018-05-16 US US16/614,015 patent/US11358977B2/en active Active
- 2018-05-16 UA UAA201911875A patent/UA124857C2/uk unknown
- 2018-05-16 ES ES18730543T patent/ES2927712T3/es active Active
- 2018-05-16 WO PCT/US2018/032939 patent/WO2018213426A1/en not_active Ceased
- 2018-05-16 MA MA049137A patent/MA49137A/fr unknown
- 2018-05-16 IL IL270680A patent/IL270680B/en unknown
- 2018-05-16 CA CA3063901A patent/CA3063901A1/en active Pending
- 2018-05-16 CN CN201880037064.5A patent/CN110740993B/zh not_active Expired - Fee Related
- 2018-05-16 BR BR112019024016A patent/BR112019024016A2/pt active Search and Examination
- 2018-05-16 EP EP18730543.8A patent/EP3625214B1/en active Active
-
2019
- 2019-11-12 CL CL2019003239A patent/CL2019003239A1/es unknown
- 2019-11-18 ZA ZA2019/07619A patent/ZA201907619B/en unknown
- 2019-11-21 CO CONC2019/0013021A patent/CO2019013021A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11358977B2 (en) | 2022-06-14 |
| AU2018271110A1 (en) | 2019-12-05 |
| CN110740993A (zh) | 2020-01-31 |
| MX2019013574A (es) | 2019-12-18 |
| UA124857C2 (uk) | 2021-12-01 |
| KR20200006128A (ko) | 2020-01-17 |
| CO2019013021A2 (es) | 2020-04-01 |
| EP3625214B1 (en) | 2022-07-06 |
| CL2019003239A1 (es) | 2020-04-17 |
| IL270680B (en) | 2022-06-01 |
| JP7104070B2 (ja) | 2022-07-20 |
| US20210155643A1 (en) | 2021-05-27 |
| MA49137A (fr) | 2021-04-21 |
| ES2927712T3 (es) | 2022-11-10 |
| BR112019024016A2 (pt) | 2020-06-09 |
| KR102714561B1 (ko) | 2024-10-10 |
| JP2020519661A (ja) | 2020-07-02 |
| WO2018213426A1 (en) | 2018-11-22 |
| ZA201907619B (en) | 2022-03-30 |
| CA3063901A1 (en) | 2018-11-22 |
| EP3625214A1 (en) | 2020-03-25 |
| CN110740993B (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013021A2 (es) | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio | |
| JOP20220130A1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
| CR20230586A (es) | N-(hydroxyalquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio | |
| ECSP20003147A (es) | Carboxamidas como moduladores de los canales de sodio | |
| MX2015009602A (es) | Piridona amidas como moduladores de canales de sodio. | |
| MX2015009591A (es) | Amidas como moduladores de canales de sodio. | |
| EA201991403A1 (ru) | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора | |
| MX379264B (es) | Profarmacos de amidas de piridona utiles como moduladores de canales de sodio. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| MX385578B (es) | Moduladores de canales de kv3 para tratar dolor. | |
| MX392452B (es) | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. | |
| EA201992719A1 (ru) | Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов | |
| EA202090268A1 (ru) | Карбоксамиды в качестве модуляторов натриевых каналов |